INVICTUS MD STRATEGIES CORP ORDINARY SH (OTCMKTS:IVITF) Stock Is Shorted More

Invictus MD Strategies Corp. (OTCMKTS:IVITF) Logo

The stock of INVICTUS MD STRATEGIES CORP ORDINARY SH (OTCMKTS:IVITF) registered an increase of 373.99% in short interest. IVITF’s total short interest was 82,000 shares in September as published by FINRA. Its up 373.99% from 17,300 shares, reported previously. With 368,200 shares average volume, it will take short sellers 0 days to cover their IVITF’s short positions.

The stock decreased 1.05% or $0.0021 during the last trading session, reaching $0.197. About 80,966 shares traded. Invictus MD Strategies Corp. (OTCMKTS:IVITF) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Invictus MD Strategies Corp. produces, distributes, and sells cannabis and related products in Canada. The company has market cap of $24.30 million. It offers medical-grade marijuana for patients and adult users. It currently has negative earnings. The firm also makes and supplies hydroponics and fertilizers.

More notable recent Invictus MD Strategies Corp. (OTCMKTS:IVITF) news were published by: Seekingalpha.com which released: “Invictus MD applies for uplisting on Nasdaq – Seeking Alpha” on January 17, 2019, also Midasletter.com with their article: “Canopy Growth Corp Continues Tweed Main Street Buildout with Invictus MD Strategies Corp (CVE:GENE) – Midas Letter” published on May 11, 2018, Seekingalpha.com published: “INew CFO at Invictus MD Strategies – Seeking Alpha” on March 15, 2019. More interesting news about Invictus MD Strategies Corp. (OTCMKTS:IVITF) were released by: Midasletter.com and their article: “Canopy Growth Corp (TSE:WEED), Aurora Cannabis Inc (TSE:ACB) Pave Way For Sector Bloodbath – Midas Letter” published on March 22, 2018 as well as Seekingalpha.com‘s news article titled: “Horizons Marijuana Life Sciences Index ETF: 2018 Q2 Update – Seeking Alpha” with publication date: July 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.